Portland, OR, June 16, 2022 (GLOBE NEWSWIRE) — According to the report published by Allied Market Research, the intravenous (IV) Ibuprofen market was valued at $5.34 million in 2020, and is estimated to reach $15.48 million by 2030, registering a CAGR of 13.38% from 2021 to 2030. The report provides a detailed analysis of changing market dynamics, top segments, value chain, key investment pockets, regional scenario, and competitive landscape.
Growing instances of arthritis, cardiovascular diseases, and cancer, increase in prevalence of bone and muscle disorders, such as ankylosing spondylitis and rheumatoid arthritis, rise in number of orthopedic hospitals and diagnostic centers, increase in prevalence of mucoskeletal diseases and orthopedic surgery, and easy availability of ibuprofen as an over the counter medication drive the growth of the intravenous (IV) ibuprofen market. On the other side, side effects associated with ibuprofen restrict the industry growth. Moreover, increase in the number of product approvals and government regulations for NSAIDs drug offer lucrative opportunities for the market.
Download Sample Report – https://www.alliedmarketresearch.com/request-sample/1387
COVID-19 Scenario-
- The COVID-19 outbreak negatively impacted the growth of the intravenous (IV) ibuprofen market as operations stalled in most hospitals due to the lockdowns in many countries.
- However, restructuring of many clinics and hospitals all over the world to increase hospital…
